Clinical neurogenetics: huntington disease
- PMID: 24176425
- DOI: 10.1016/j.ncl.2013.05.004
Clinical neurogenetics: huntington disease
Abstract
Huntington disease (HD) is an autosomal dominant, adult-onset, progressive neurodegenerative disease characterized by the triad of abnormal movements (typically chorea), cognitive impairment, and psychiatric problems. It is caused by an expanded CAG repeat in the gene encoding the protein huntingtin on chromosome 4 and causes progressive atrophy of the striatum as well as cortical and other extrastriatal structures. Genetic testing has been available since 1993 to confirm diagnosis in affected adults and for presymptomatic testing in at-risk individuals. This review covers HD signs, symptoms, and pathophysiology; current genetic testing issues; and current and future treatment strategies.
Keywords: CAG repeat disorder; Huntingtin; Preimplantation genetic diagnosis; Presymptomatic genetic testing; Striatum; Tetrabenazine.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Huntington disease: pathogenesis and treatment.Neurol Clin. 2015 Feb;33(1):101-14. doi: 10.1016/j.ncl.2014.09.003. Neurol Clin. 2015. PMID: 25432725 Review.
-
Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.Arch Neurol. 2007 Jun;64(6):813-9. doi: 10.1001/archneur.64.6.813. Arch Neurol. 2007. PMID: 17562929
-
A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.Ann Neurol. 2001 Sep;50(3):373-80. Ann Neurol. 2001. Corrected and republished in: Ann Neurol. 2001 Dec;50(6):373-80. doi: 10.1002/ana.1312. PMID: 11558794 Corrected and republished.
-
[Huntington's chorea: clinical aspects, genetics and current diagnosis].Ther Umsch. 1995 Dec;52(12):814-20. Ther Umsch. 1995. PMID: 8539653 German.
-
Therapeutic options for Huntington's disease.Curr Opin Investig Drugs. 2003 Jan;4(1):51-4. Curr Opin Investig Drugs. 2003. PMID: 12625029 Review.
Cited by
-
Factors Influencing the Total Functional Capacity Score as a Critical Endpoint in Huntington's Disease Research.Biomedicines. 2023 Dec 17;11(12):3336. doi: 10.3390/biomedicines11123336. Biomedicines. 2023. PMID: 38137557 Free PMC article.
-
Basal ganglia for beginners: the basic concepts you need to know and their role in movement control.Front Syst Neurosci. 2023 Aug 3;17:1242929. doi: 10.3389/fnsys.2023.1242929. eCollection 2023. Front Syst Neurosci. 2023. PMID: 37600831 Free PMC article. Review.
-
Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington's Disease.J Health Econ Outcomes Res. 2021 Jun 21;8(1):99-105. doi: 10.36469/001c.24620. J Health Econ Outcomes Res. 2021. PMID: 34183975 Free PMC article.
-
Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task.Neural Regen Res. 2020 Aug;15(8):1518-1525. doi: 10.4103/1673-5374.274342. Neural Regen Res. 2020. PMID: 31997817 Free PMC article.
-
Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data.J Neurol. 2018 Jul;265(7):1573-1579. doi: 10.1007/s00415-018-8880-1. Epub 2018 May 3. J Neurol. 2018. PMID: 29725840
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
